房建工程地基基础施工关键技术探究

地基处理技术是近年来我国房屋建筑工程施工中一种较常见的施工处理技术,多见于房屋建筑工程中的软土地基施工环节。通过以往的房屋建筑经验,如果直接在软土地基上进行建筑施工,地基区域软土很容易会影响房屋建筑工程的稳定性,所以,在针对这一部分软土区域的施工环节,需要针对拟施工的地基软土区域进行处理,提升其软土的稳定性。到目前,地基处理技术已经在我国房屋建筑工程施工中广泛应用,这一技术应用过程中存在的不足也逐渐凸显,如何针对这一技术的不足予以完善,以此提升地基处理技术对房屋建筑质量的积极影响,成为了现阶段房屋建筑地基基础施工质量提升的重要环节之一。     

Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results

Aims: The EINSTEIN-Extension trial (EINSTEIN-EXT) found that continued treatment with rivaroxaban for an additional 6 or 12 months (vs placebo) after 6–12 months of initial anticoagulation significantly reduced the risk of recurrent venous thromboembolism (VTE) with a small non-significant increased risk of major bleeding (none fatal or in critical site). This study aimed to compare total healthcare cost between rivaroxaban and placebo, based on the EINSTEIN-EXT event rates.

Methods: Total healthcare cost was calculated as the sum of treatment and clinical event costs from a US managed care perspective. Treatment duration and event rates were obtained from the EINSTEIN-EXT study. Adjustment on treatment duration was made by assuming a 10% non-adherence rate. Drug costs were based on wholesale acquisition costs. Cost estimates for clinical events (i.e. recurrent deep vein thrombosis [DVT], recurrent pulmonary embolism, major bleeding, clinically relevant non-major bleeding) were determined from the literature. Results were examined over a ±20% range of each cost component and over 95% confidence intervals (CIs) of event rate differences in deterministic (one-way) and probabilistic sensitivity analyses (PSA).

Results: Total healthcare cost was $1,454 lower for rivaroxaban-treated (vs placebo-treated) patients in the base-case, with a lower clinical event cost fully offsetting drug cost. The cost savings of recurrent DVT alone (–$3,102) was greater than drug cost ($2,723). Total healthcare cost remained lower for rivaroxaban in the majority (73%) of PSA (cost difference [95% CI]?=?–$1,454 [–$2,396, $1,231]).

Limitations: This study was conducted over the 1-year observation period of the EINSTEIN-EXT trial, which limited “real-world” applicability and examination of long-term economic impact. Assumptions on drug and clinical event costs were US-based and, thus, not applicable to other healthcare systems.

Conclusions: Total healthcare costs were estimated to be lower for patients continuing rivaroxaban therapy compared to those receiving placebo in VTE patients who had completed 6–12 months of VTE treatment.     

Psychometric validation of anti-clot treatment scale and treatment satisfaction questionnaire for medication version II in Japanese patients with atrial fibrillation

Aims: The Anti-Clot Treatment Scale (ACTS) and Treatment Satisfaction Questionnaire for Medication version II (TSQM-II) are validated treatment satisfaction patient-reported outcome (PRO) instruments. The ACTS includes two domains: Burdens and Benefits; the TSQM-II includes four: Effectiveness, Side Effects, Convenience, and Global Satisfaction. Japanese-language versions of the ACTS and TSQM-II have been developed and linguistically validated. This study aimed to assess their psychometric properties in Japanese patients with atrial fibrillation (AF).

Materials and methods: ACTS and TSQM-II data from 534 patients with AF were collected in a Japanese post-marketing surveillance study of a direct oral-anticoagulant, rivaroxaban. Four key psychometric properties, in line with best practice guidelines from the US Food and Drug Administration, were examined using traditional psychometric methods: acceptability, scaling assumptions, reliability (i.e. internal consistency reliability, test-retest reliability), and construct validity (i.e. convergent validity and known groups).

Results: ACTS Burdens and Benefits and TSQM-II Effectiveness, Convenience, and Global Satisfaction scales were found to be acceptable (e.g. item-level missing data at baseline <4%), with all scales having good internal consistency (Cronbach’s alpha > 0.80). test-retest reproducibility intraclass correlation coefficients for the ACTS Burdens and Benefits were 0.59 and 0.65, respectively, and between 0.54–0.61 for the TSQM-II scales. Known-groups validity for the ACTS and TSQM-II was supported by differences in scale scores by positive and negative impact (p?<?0.05). Correlations between the ACTS and TSQM-II (convergent validity) were lower than expected (range r?=?0.09–0.48), but in line with the original ACTS development study.

Limitations: Evaluation of test-retest reproducibility was limited by assessment period, which was longer (3 months) than recommended guidelines (usually up to 2 weeks).

Conclusions: Overall, Japanese versions of ACTS and TSQM-II scales satisfied internal consistency reliability and traditional validity criteria. Our study supports the ACTS and TSQM-II as appropriate PRO instruments to measure satisfaction with anticoagulant treatment in Japanese patients with AF.

Trial registration: NCT01598051, clinicaltrials.gov; registered April 20, 2012.     

论城镇污水处理BOT项目的法律缺陷问题

城镇污水的资源化处理已成为世界潮流，是人类实现可持续发展的重要途径之一。我国城镇污水处理BOT项目面临的法律缺陷主要包括法律位阶较低，条文内容相当简陋，存在许多立法空白，条文存在诸多法律障碍等，针对污水处理BOT项目的法律缺陷，应由国务院制定BOT行政法规，明确特许协议性质和政府的法律地位，构建完整的、系统的城镇污水处理BOT项目的法律制度。     

城市污泥厌氧消化处理研究进展

对城市污泥利用厌氧消化处理的工艺前处理方法及其它相关相关研究进行了综述，并指出了城市污泥厌氧处理中今后要解决的问题和应用前景。     

债务重组的会计问题研究

本文根据新会计制度的规定,就债务重组的基本原理五种债务重组方式的会计处理事项分别作了说明,并对中外关于债务重组的处理方法进行了比较,找出了其中的差异。为了寻找更为完善的对债务重组的会计处理方法,本文对新会计制度关于债务重组的某些不足之处进行了讨论,提出了相应的意见和建议。     

钢筋混凝土现浇楼板裂缝成因分析及防治措施

文章对某工业厂房现浇楼板产生裂缝进行调查,分析了裂缝的特征和产生的原因,介绍了防治裂缝的措施以及修补裂缝的方法。     

煤代油工程污水处理工艺的选择

文章通过分析巴陵分公司煤代油工程的污水排放特性及技术条件,探讨了污水处理工艺的选择。     

Dominance Statistics: A Simulation Study on the d Statistic

Quality &; Quantity - Cliff (1993) has proposed the use of a measure of effect size alternative to traditionalmean differences: δ {? = Pr(xi1 &;gt; xj2) - Pr(xi1 &;lt; xj2)}which,...     

医药合谋与医疗体制变迁的一个经济解释及政策含义

医药合谋,即医生倾向于开昂贵的药方,是医疗服务提供者在医疗服务价格被政府管制于均衡价格之下而被迫采取的措施.在医药合谋下,处方药的供给商很难通过价格杠杆机制来推广自己生产、经营的药品.因此,要使价格机制发生作用,必须解除对医疗服务价格的管制,让市场来决定医疗服务价格.